Atherogenic circulating lipoproteins in ischemic stroke
- PMID: 39713216
- PMCID: PMC11659270
- DOI: 10.3389/fcvm.2024.1470364
Atherogenic circulating lipoproteins in ischemic stroke
Abstract
The fundamental role of qualitative alterations of lipoproteins in the early development of atherosclerosis has been widely demonstrated. Modified low-density lipoproteins (LDL), such as oxidized LDL (oxLDL), small dense LDL (sdLDL), and electronegative LDL [LDL(-)], are capable of triggering the atherogenic process, favoring the subendothelial accumulation of cholesterol and promoting inflammatory, proliferative, and apoptotic processes characteristic of atherosclerotic lesions. In contrast, high-density lipoprotein (HDL) prevents and/or reverses these atherogenic effects. However, LDL's atherogenic and HDL's anti-atherogenic actions may result altered in certain pathological conditions. The molecular mechanisms underlying the impaired effects of altered lipoproteins have been studied in numerous in vitro and in vivo studies, and have been extensively analyzed in coronary atherosclerosis, especially in the context of pathologies such as dyslipidemia, diabetes, obesity, and metabolic syndrome. However, the corresponding studies are scarcer in the field of ischemic stroke, despite carotid arteriosclerosis progression underlies at least 20% of ischemic strokes. The present review relates qualitative alterations of LDL and HDL with the development of carotid arteriosclerosis and the occurrence of ischemic stroke.
Keywords: HDL; carotid atherosclerosis; electronegative LDL; ischemic stroke; oxidized LDL; small dense LDL.
© 2024 Benitez, Puig, Camps-Renom and Sánchez-Quesada.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Alterations in LDL and HDL after an ischemic stroke associated with carotid atherosclerosis are reversed after 1 year.J Lipid Res. 2025 Feb;66(2):100739. doi: 10.1016/j.jlr.2024.100739. Epub 2024 Dec 31. J Lipid Res. 2025. PMID: 39746448 Free PMC article.
-
LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins.PLoS One. 2022 Jul 28;17(7):e0272050. doi: 10.1371/journal.pone.0272050. eCollection 2022. PLoS One. 2022. PMID: 35901111 Free PMC article.
-
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.Eur Heart J. 1998 Feb;19 Suppl A:A24-30. Eur Heart J. 1998. PMID: 9519339 Review.
-
Lipoprotein profile in patients who survive a stroke.Neuro Endocrinol Lett. 2011;32(4):496-501. Neuro Endocrinol Lett. 2011. PMID: 21876499
-
The Oxidized Lipoproteins In Vivo: Its Diversity and Behavior in the Human Circulation.Int J Mol Sci. 2023 Mar 17;24(6):5747. doi: 10.3390/ijms24065747. Int J Mol Sci. 2023. PMID: 36982815 Free PMC article. Review.
Cited by
-
Apolipoprotein B and Glycemic Dysregulation: New Predictors of Type 2 Diabetes in High-Cardiovascular-Risk Populations.J Pers Med. 2025 Apr 23;15(5):163. doi: 10.3390/jpm15050163. J Pers Med. 2025. PMID: 40423035 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources